Conduit Pharmaceuticals (CDT) Competitors $0.90 +0.03 (+3.26%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.91 +0.01 (+1.63%) As of 09:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. CDIO, CVM, LSTA, NNVC, EQ, MTEX, ABP, UBX, EDSA, and LPCNShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include Cardio Diagnostics (CDIO), CEL-SCI (CVM), Lisata Therapeutics (LSTA), NanoViricides (NNVC), Equillium (EQ), Mannatech (MTEX), Abpro (ABP), Unity Biotechnology (UBX), Edesa Biotech (EDSA), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Cardio Diagnostics CEL-SCI Lisata Therapeutics NanoViricides Equillium Mannatech Abpro Unity Biotechnology Edesa Biotech Lipocine Conduit Pharmaceuticals (NASDAQ:CDT) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking. Do institutionals and insiders hold more shares of CDT or CDIO? 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 30.9% of Conduit Pharmaceuticals shares are held by company insiders. Comparatively, 22.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, CDT or CDIO? Conduit Pharmaceuticals has higher earnings, but lower revenue than Cardio Diagnostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$540K-$39.33-0.02Cardio Diagnostics$34.89K596.03-$8.38MN/AN/A Do analysts rate CDT or CDIO? Cardio Diagnostics has a consensus price target of $2.00, indicating a potential upside of 401.50%. Given Cardio Diagnostics' higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CDT or CDIO? In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Conduit Pharmaceuticals and 2 mentions for Cardio Diagnostics. Conduit Pharmaceuticals' average media sentiment score of 0.66 beat Cardio Diagnostics' score of 0.43 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Conduit Pharmaceuticals Positive Cardio Diagnostics Neutral Which has more risk & volatility, CDT or CDIO? Conduit Pharmaceuticals has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.73, indicating that its stock price is 273% more volatile than the S&P 500. Is CDT or CDIO more profitable? Conduit Pharmaceuticals has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,732.03%. Conduit Pharmaceuticals' return on equity of 0.00% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -328.67% Cardio Diagnostics -22,732.03%-258.85%-191.20% Does the MarketBeat Community believe in CDT or CDIO? Cardio Diagnostics received 3 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Conduit Pharmaceuticals an outperform vote while only 80.00% of users gave Cardio Diagnostics an outperform vote. CompanyUnderperformOutperformConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesCardio DiagnosticsOutperform Votes480.00% Underperform Votes120.00% SummaryConduit Pharmaceuticals beats Cardio Diagnostics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.97M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.026.7921.7317.82Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book-1.455.866.464.00Net Income-$540,000.00$141.86M$3.20B$247.23M7 Day Performance44.58%4.50%2.86%1.45%1 Month Performance-17.76%-12.65%-8.55%-6.24%1 Year Performance-99.71%-11.06%10.47%0.60% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit Pharmaceuticals0.5365 of 5 stars$0.90+3.3%N/A-99.7%$5.97MN/A-0.023Gap DownHigh Trading VolumeCDIOCardio Diagnostics2.116 of 5 stars$0.33+7.1%$2.00+511.2%-60.0%$17.06M$34,890.000.001Short Interest ↑Gap DownCVMCEL-SCIN/A$0.21-3.5%N/A-84.7%$16.71MN/A-0.4343Analyst ForecastLSTALisata Therapeutics2.422 of 5 stars$1.90-4.5%$15.00+689.5%-23.3%$16.38M$1M-0.7630News CoverageGap DownNNVCNanoViricidesN/A$1.04-3.7%N/A+15.7%$16.27MN/A-1.4420Positive NewsGap DownEQEquillium3.2096 of 5 stars$0.45-4.5%$3.00+564.9%-73.8%$16.07M$41.10M-3.2240Short Interest ↓Positive NewsGap DownMTEXMannatech1.1607 of 5 stars$8.37+0.2%N/A+25.6%$15.91M$117.87M-10.33250Gap UpABPAbproN/A$0.31-10.2%$4.00+1,210.6%N/A$15.81M$122,000.000.0015High Trading VolumeUBXUnity Biotechnology4.2371 of 5 stars$0.93+2.8%$5.33+476.5%-35.3%$15.61M$240,000.00-0.7160Upcoming EarningsPositive NewsEDSAEdesa Biotech3.2531 of 5 stars$2.18-5.6%$21.00+863.3%-43.6%$15.25MN/A-1.1720Short Interest ↓Gap DownLPCNLipocine2.6988 of 5 stars$2.84-5.6%$10.00+252.1%-43.0%$15.19M$11.20M-3.7410Analyst ForecastGap Down Remove Ads Related Companies and Tools Related Companies Cardio Diagnostics Alternatives CEL-SCI Alternatives Lisata Therapeutics Alternatives NanoViricides Alternatives Equillium Alternatives Mannatech Alternatives Abpro Alternatives Unity Biotechnology Alternatives Edesa Biotech Alternatives Lipocine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDT Stock Free CDT Stock Alerts